GSK’s Arexvy Approved in U.S. for At-Risk Adults 18–49

The GSK plc vaccine Arexvy receives expanded approval from the U.S. Food and Drug Administration, allowing use in adults aged 18–49 who face a higher risk of severe respiratory illness caused by Respiratory Syncytial Virus (RSV). GSK plc has announced…








